We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge
Read MoreHide Full Article
Mersana Therapeutics, Inc., (MRSN - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MRSN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Mersana Therapeutics could be a solid choice for investors.
Current Quarter Estimates for MRSN
In the past 30 days, four estimates have gone higher for Mersana Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 38 cents a share 30 days ago, to a loss of 30 cents today, a move of 21.1%.
Current Year Estimates for MRSN
Meanwhile, Mersana Therapeutics’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.48 per share 30 days ago to a loss of $1.27 per share today, an increase of 14.2%.
The stock has also started to move higher lately, adding 139.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Why Mersana Therapeutics (MRSN) Could Be Positioned for a Surge
Mersana Therapeutics, Inc., (MRSN - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
These positive earnings estimate revisions suggest that analysts are becoming more optimistic on MRSN’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Mersana Therapeutics could be a solid choice for investors.
Current Quarter Estimates for MRSN
In the past 30 days, four estimates have gone higher for Mersana Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 38 cents a share 30 days ago, to a loss of 30 cents today, a move of 21.1%.
Current Year Estimates for MRSN
Meanwhile, Mersana Therapeutics’s current year figures are also looking quite promising, with five estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of $1.48 per share 30 days ago to a loss of $1.27 per share today, an increase of 14.2%.
Mersana Therapeutics, Inc. Price and Consensus
Mersana Therapeutics, Inc. price-consensus-chart | Mersana Therapeutics, Inc. Quote
Bottom Line
The stock has also started to move higher lately, adding 139.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>